Spyre Therapeutics Inc

For the period ended Dec 31, 2023. Filed Feb 29, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 29, 2024

SYRE$103.86+7.5%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations

(In thousands, except share and per share amounts)

	Year Ended December 31,
	2023	2022	2021
Revenue:
License	$—	$—	$12,000
Development fee and royalty	886	2,329	6,739
Total revenue	886	2,329	18,739
Operating expenses:
Research and development (1)	89,504	58,579	57,069
General and administrative	39,946	28,531	27,319
Acquired in-process research and development	130,188	—	—
Gain on sale of in-process research and development asset	(16,449)	—	—
Total operating expenses	243,189	87,110	84,388
Loss from operations	(242,303)	(84,781)	(65,649)
Other (expense) income:
Interest income	6,147	837	111
Change in fair value of forward contract liability	(83,530)	—	—
Other expense, net	(19,130)	(7)	(122)
Total other (expense) income	(96,513)	830	(11)
Loss before income tax expense	(338,816)	(83,951)	(65,660)
Income tax benefit (expense)	26	136	(141)
Net loss	$(338,790)	$(83,815)	$(65,801)
Net loss per share, basic and diluted	$(49.12)	$(24.86)	$(25.02)
Weighted-average common shares outstanding, basic and diluted	6,897,065	3,371,231	2,629,784

(1)Includes $48.5 million in related party expenses for the year ended December 31, 2023 andno related party expenses for the year ended months ended December 31, 2022 and 2021.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.